Evaluation of the treatment symptomatic efficacy between groups: changes between baseline and final visit. Intention to treat analysis with the last observation carried forward
| Changes between baseline and final visit (n = 301) | NRD101 (n = 131) | Diacerein (n = 85) | Placebo (n = 85) | Analysis of variance (p value) |
|---|---|---|---|---|
| Results are shown as mean (SD). | ||||
| *For change assessment, the 0–24 Lequesne’s index has been translated into a 0–100 scale. | ||||
| Pain (0–100 VAS) | −33.5 (28.5) | −33.9 (25.7) | −34.5 (27.4) | 0.96 |
| Lequesne’s algofunctional index* | −20.0 (16.5) | −18.8 (14.7) | −18.9 (16.9) | 0.84 |
| Patient’s global assessment (0–100 VAS) | −29.7 (26.9) | −32.8 (24.0) | −31.1 (31.7) | 0.82 |
| Percentage of painful days (0–100 VAS) | −43.5 (40.3) | −45.6 (37.8) | 46.6 (37.2) | 0.83 |